| Literature DB >> 34070340 |
Sveva Maria Nusca1, Attilio Parisi2, Paolo Mercantini3, Marcello Gasparrini4, Francesco Antonio Pitasi5, Alessandra Lacopo5, Vincenzo Colonna5, Giulia Stella5, Claudia Cerulli2, Elisa Grazioli2, Eliana Tranchita2, Flavia Santoboni5, Eleonora Latini5, Donatella Trischitta5, Mario Vetrano5, Vincenzo Visco6, Antonio Pavan6, Maria Chiara Vulpiani5.
Abstract
This pilot study explores the effects of a post-operative physical exercise program on the quality of life (QoL) and functional and nutritional parameters of patients that underwent laparoscopic colorectal cancer surgery, compared to usual care alone. The intervention group (IG) attended a 2-month-long supervised and combined exercise-training program during the post-operative period. Both IG and control group (CG) participated in the QoL, functional, and nutritional assessments before exercise training (T0), 2 months after the beginning of the exercise (end of treatment) (T1), and 2 (T2) and 4 (T3) months from the end of treatment. Eleven patients with colorectal cancer that underwent laparoscopic surgery were enrolled (six intervention; five control). The IG showed significant improvements compared to the CG in "Physical functioning" (PF2) (p = 0.030), "Cognitive functioning" (CF) (p = 0.018), and "Fatigue" (FA) (p = 0.017) of the European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) at T1; in SMWT (p = 0.022) at T1; in PF2 (p = 0.018) and FA (p = 0.045) of EORTC QLQ-C30 at T2, in phase angle (PhA) of bioelectrical impedance analysis (p = 0.022) at T3. This pilot study shows that a post-operative, combined, and supervised physical exercise program may have positive effects in improving the QoL, functional capacity, and nutritional status in patients that undergo laparoscopic colorectal cancer surgery.Entities:
Keywords: Enhanced Recovery after Surgery (ERAS); combined exercise; oncology; physical exercise; quality of life; supervised exercise
Year: 2021 PMID: 34070340 PMCID: PMC8197504 DOI: 10.3390/ijerph18115632
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Consort flow diagram.
Patients’ demographic, clinicopathologic, and operative characteristics at baseline.
| Variables | IG ( | CG ( | |
|---|---|---|---|
| Age-(median, range) | 63.5 (43.0–80.0) | 73.0 (51.0–80.0) | 0.580 |
| Sex-n. (%) | |||
| Male | 5 (83.3) | 2(33.3) | |
| Female | 1 (16.7) | 3 (66.7) | |
| BMI-(median, range) | 21.4 (17.2–25.7) | 24.0 (22.0–41.4) | 0.200 |
| KPS (median, range) | 80.0 (70.0–80.0) | 80.0 (70.0–80.0) | 0.540 |
| Neoplasm type-n. (%) | |||
| Colon cancer | 5 (83.3) | 3 (66.7) | |
| Rectal cancer | 1 (16.7) | 2 (33.3) | |
| TNM Cancer stage-n. (%) | |||
| Stage IIA | 1 (16.7) | 1 (20.0) | |
| Stage IIB | 2 (33.3) | 1 (20.0) | |
| Stage IIIB | 3 (50.0) | 3 (60.0) | |
| Type of resection-n. (%) | |||
| Colon * | 5 (83.3) | 3 (66.7) | |
| Rectum ** | 1 (16.7) | 2 (33.3) | |
| New Stoma-n. (%) | 0 (0.0) | 0 (0.0) | |
| Chemotherapy-n. (%) | 6 (100.0) | 5 (100.0) | |
| EORTC QLQ-C30-(median, range) | |||
| QL2 | 50.0 (16.7–83.3) | 58.0 (50.0–83.3) | 0.910 |
| PF2 | 93 (60.0–100.0) | 90.0 (87.0–93.0) | 0.733 |
| RF2 | 66.5 (33.0–100.0) | 67.0 (50.0–100.0) | 0.692 |
| EF | 79.5 (42.0–93.0) | 75.0 (57.0–83.0) | 0.580 |
| CF | 100.0 (83.0–100.0) | 83.3 (83.0–84.0) | 0.442 |
| SF | 67.0 (33.0–83.0) | 84.0 (66.6–100.0) | 0.443 |
| FA | 38.8 (0.0–66.7) | 33.3 (22.0–53.3) | 0.854 |
| NV | 0.0 (0.0–50.0) | 0.0 (0.0–16.7) | 0.560 |
| PA | 16.7 (0.0–66.7) | 0.0 (0.0–33.3) | 0.561 |
| DY | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.892 |
| SL | 33.3 (0.0–66.7) | 0.0 (0.0–33.3) | 0.609 |
| AP | 33.4 (0.0–100.0) | 33.3 (0.0–66.6) | 0.564 |
| CO | 16.7 (0.0–66.7) | 0.0 (0.0–33.3) | 0.242 |
| DI | 16.7 (0.0–33.3) | 0.0 (0.0–33.3) | 0.326 |
| FI | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.892 |
Abbreviations: IG, Intervention Group; CG, Control Group; BMI, Body Mass Index; KPS: Karnofsky Performance Status; TNM = tumor–node–metastasis; * Includes right and left hemicolectomy and sigmoid resection. ** Includes anterior resection. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA, Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale.
EORTC QLQ-C30: between-group analysis at 2 months after the beginning of the exercise (end of treatment) (T1).
| EORTC QLQ-C30 | T1 Group IG | T1 Group CG | |
|---|---|---|---|
| QL2 | 70.9 (25.0–100.0) | 62.5 (41.7–66.7) | 0.330 |
| PF2 | 96.5 (86.7–100.0) | 83.4 (60.0–87.0) | 0.030 * |
| RF2 | 92.0 (50.0–100.0) | 83.3 (83.0–84.0.) | 0.228 |
| EF | 87.5 (58.0–100.0) | 75.0 (58.3–75.0) | 0.249 |
| CF | 100.0 (100.0–100.0) | 74.8 (66.6–100.0) | 0.018 * |
| SF | 68.5 (50.0–100.0) | 83.3 (50.0–100.0) | 0.912 |
| FA | 22.8 (0.0–33.3) | 55.6 (33.3–66.7) | 0.017 * |
| NV | 0.0 (0.0–16.6) | 0.0 (0.0–0.0) | 0.414 |
| PA | 0.0 (0.0–33.3) | 8.4 (0.0–16.7) | 0.807 |
| DY | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1000 |
| SL | 16.7 (0.0–66.7) | 50.0 (0.0–66.7) | 0.309 |
| AP | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.759 |
| CO | 0.0 (0.0–66.7) | 16.7 (0.0–33.3) | 0.429 |
| DI | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.789 |
| FI | 0.0 (0.0–0.0) | 0.0 (0.0–33.3) | 0.221 |
Abbreviations: IG, Intervention Group; CG, Control Group; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA, Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties. * p-value < 0.05.
EORTC QLQ-C30: between-group analysis at 2 months from the end of the exercise training (T2).
| EORTC QLQ-C30 | T2 Group IG | T2 Group CG | |
|---|---|---|---|
| (Median, Range) | (Median, Range) | ||
| QL2 | 87.5 (75.0–91.7) | 75.0 (66.7–83.3) | 0.134 |
| PF2 | 100.0 (93.3–100.0) | 82.0 (73.3–87.0) | 0.018 * |
| RF2 | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 1.000 |
| EF | 95.8 (66.7–100.0) | 91.7 (75.0–100.0) | 0.762 |
| CF | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 1.000 |
| SF | 91.7 (83.3–100.0) | 92.5 (83.0–100.0) | 1.000 |
| FA | 5.5 (0.0–11.0) | 19.5 (11.0–22.2) | 0.045 * |
| NV | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.000 |
| PA | 0.0 (0.0–33.3) | 0.0 (0.0–16.7) | 0.850 |
| DY | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.000 |
| SL | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 1.000 |
| AP | 0.0 (0.0–0.0) | 0.0 (0.0–33.3) | 0.317 |
| CO | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 1.000 |
| DI | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 1.000 |
| FI | 0.0 (0.0–0.0) | 0.0 (0.0–33.3) | 0.317 |
Abbreviations: IG, Intervention Group; CG, Control Group; EORTC European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA, Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties. * p-value < 0.05.
EORTC QLQ-C30: between-group analysis at 4 months from the end of the exercise training (T3).
| EORTC QLQ-C30 | T3 Group IG | T3 Group CG | |
|---|---|---|---|
| (Median, Range) | (Median, Range) | ||
| QL2 | 79.2 (50.0–100.0) | 79.2 (75.0–100.0) | 0.664 |
| PF2 | 93.7 (60.0–100.0) | 91.7 (87.0–100.0) | 0.914 |
| RF2 | 100.0 (80.0–100.0) | 100.0 (100.0–100.0) | 0.414 |
| EF | 87.9 (50.0–100.0) | 89.4 (50.0–100.0) | 0.914 |
| CF | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 1.000 |
| SF | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 1.000 |
| FA | 11.1 (0.0–44.0) | 11.6 (0.0–33.0) | 0.577 |
| NV | 0.0 (0.0–20.0) | 0.0 (0.0–16.6) | 0.693 |
| PA | 0.0 (0.0–33.3) | 0.0 (0.0–23.3) | 0.793 |
| DY | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.759 |
| SL | 16.7 (0.0–66.0) | 16.7 (0.0–66.7) | 0.818 |
| AP | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.789 |
| CO | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.895 |
| DI | 0.0 (0.0–66.6) | 0.0 (0.0–66.7) | 0.648 |
| FI | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.000 |
Abbreviations: IG, Intervention Group; CG, Control Group; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA, Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties.
PSQI, HADS, Functional and Nutritional parameters: between-group analysis at 2 months after the beginning of the exercise (end of treatment) (T1), at 2 (T2), and 4 (T3) months from the end of the exercise training.
| Group IG | Group CG | ||
|---|---|---|---|
| (Median, Range) | (Median, Range) | ||
| GLOBAL PSQI | |||
| T0 | 8.5 (2.0–13.0) | 7.0 (4.0–15.0) | 0.855 |
| T1 | 5.0 (3.0–10.0) | 10.0 (4.0–12.0) | 0.133 |
| T2 | 3.0 (1.0–7.0) | 4.0 (2.0–8.0) | 0.554 |
| T3 | 5.5 (3.0–10.0) | 5.0 (2.0–9.0) | 0.668 |
| HADS: ANXIETY | |||
| T0 | 7.0 (3.0–17.0) | 6.0 (4.0–9.0) | 0.783 |
| T1 | 5.5 (0.0–14.0) | 6.0 (2.0–8.0) | 0.745 |
| T2 | 4.0 (2.0–9.0) | 5.0 (4.0–6.0) | 0.554 |
| T3 | 3.0 (1.0–9.0) | 3.5 (0.0–8.0) | 0.086 |
| HADS: DEPRESSION | |||
| T0 | 8.5 (2.0–14.0) | 6.0 (4.0–8.0) | 0.410 |
| T1 | 4.5 (1.0–13.0) | 5.5 (2.0–7.0) | 0.830 |
| T2 | 2.5 (0.0–16.0) | 6.0 (3.0–7.0) | 0.384 |
| T3 | 2.0 (1.0–10.0) | 3.0 (0.0–8.0) | 0.104 |
| SMWT | |||
| T0 | 590.0 (360.0–685.0) | 375.0 (330.0–560.0) | 0.100 |
| T1 | 625.0 (400.0–815.0) | 359.0 (320.0–510.0) | 0.022 * |
| T2 | 573.0 (445.0–815.0) | 500.0 (400.0–535.0) | 0.067 |
| T3 | 580.0 (445.0–750.0) | 450.0 (400.0–600.0) | 0.100 |
| SPPB | |||
| T0 | 11.0 (7.0–12.0) | 11.0 (9.0–11.0) | 1.000 |
| T1 | 11.0 (10.0–12.0) | 11.0 (9.0–11.0) | 0.161 |
| T2 | 12.0 (10.0–12.0) | 11.0 (10.0–12.0) | 0.287 |
| T3 | 12.0 (10.0–12.0) | 10.0 (9.0–12.0) | 0.169 |
| HANDGRIP | |||
| T0 | 57.0 (28.0–62.0) | 41.0 (40.0–59.0) | 0.272 |
| T1 | 57.0 (28.0–62.0) | 50.0 (41.0–55.0) | 0.099 |
| T2 | 57.0 (37.0–62.0) | 52.0 (41.0–58.0) | 0.233 |
| T3 | 56.0 (39.0–65.0) | 50.0 (41.0–55.0) | 0.120 |
| BMI | |||
| T0 | 21.4 (17.2–25.7) | 24.0 (22.0–41.4) | 0.200 |
| T1 | 21.8 (18.6–26.8) | 24.0 (20.0–39.5) | 0.465 |
| T2 | 22.6 (19.5–27.6) | 22.5 (20.0–39.5) | 0.927 |
| T3 | 23.0 (21.0–28.3) | 22.5 (20.2–39.6) | 0.647 |
| SMI-BIA | |||
| T0 | 8.9 (7.6–9.6) | 7.8 (6.4–8.6) | 0.086 |
| T1 | 9.2 (7.6–10.5) | 8.0 (6.5–10.7) | 0.310 |
| T2 | 9.7 (7.1–10.5) | 8.0 (7.1–10.8) | 0.582 |
| T3 | 9.4 (7.0–9.7) | 8.0 (7.4–10.9) | 0.712 |
| PhA-BIA | |||
| T0 | 5.6 (4.1–5.7) | 4.6 (4.5–5.6) | 0.460 |
| T1 | 5.6 (4.4–6.5) | 5.0 (4.4–5.1) | 0.141 |
| T2 | 5.8 (5.0–6.5) | 5.0 (4.4–5.3) | 0.054 |
| T3 | 5.8 (5.0–6.1) | 5.0 (4.4–5.3) | 0.022 * |
Abbreviations: IG, Intervention Group; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale, 6MWT, 6 Minute Walking Test; SPPB, Short Physical Performance Battery; BMI, Body Mass Index; SMI-BIA, Skeletal Muscle Index Bio Impedance Analysis; PhA BIA, Phase Angle Bio Impedance Analysis. * p-value < 0.05.
IG at baseline (T0), 2 months after the beginning of exercise (end of treatment) (T1), at 2 (T2), and 4 (T3) months from the end of the exercise training; p-value within IG.
|
| Follow-up | |||||
|---|---|---|---|---|---|---|
| t0vst1 | t0vst2 | t0vst3 | t1vst2 | t1vst3 | t2vst3 | |
|
| ||||||
| QL2 | 0.104 | 0.066 | 0.074 | 0.141 | 0.339 | 1.000 |
| PF2 | 0.197 | 0.068 | 0.715 | 0.180 | 0.593 | 0.109 |
| RF2 | 0.078 | 0.180 | 0.068 | 0.180 | 0.109 | 1.000 |
| EF | 0.116 | 0.068 | 0.075 | 0.655 | 0.893 | 1.000 |
| CF | 0.317 | 1.000 | 0.317 | 1.000 | 1.000 | 1.000 |
| SF | 0.078 | 0.068 | 0.027 * | 0.180 | 0.068 | 0.157 |
| FA | 0.141 | 0.109 | 0.046 * | 0.285 | 0.269 | 1.000 |
| NV | 0.285 | 1.000 | 1.000 | 0.317 | 0.414 | 0.317 |
| PA | 0.131 | 0.785 | 0.131 | 0.655 | 1.000 | 0.317 |
| DY | 0.317 | 1.000 | 1.000 | 1.000 | 0.317 | 1.000 |
| SL | 0.102 | 0.102 | 0.077 | 1.000 | 0.655 | 1.000 |
| AP | 0.141 | 0.317 | 0.221 | 0.317 | 0.564 | 0.157 |
| CO | 0.180 | 1.000 | 0.197 | 0.317 | 1.000 | 1.000 |
| DI | 0.564 | 0.317 | 0.705 | 0.317 | 1.000 | 0.317 |
| FI | 0.317 | 1.000 | 0.317 | 1.000 | 1.000 | 1.000 |
|
| ||||||
| Global | 0.078 | 0.144 | 0.339 | 0.180 | 0.752 | 0.357 |
|
| ||||||
| Anxiety | 0.236 | 1.000 | 0.078 | 1.000 | 0.248 | 0.102 |
| Depression | 0.673 | 0.854 | 0.068 | 1.000 | 0.115 | 0.581 |
|
| ||||||
| SMWT | 0.028 * | 0.173 | 0.075 | 0.465 | 0.172 | 0.892 |
| HANDGRIP | 0.715 | 0.917 | 0.600 | 0.285 | 0.500 | 0.686 |
| SPPB | 0.285 | 0.197 | 0.109 | 0.317 | 0.564 | 1.000 |
|
| ||||||
| BMI | 0.068 | 0.080 | 0.060 | 0.144 | 0.055 | 0.080 |
| SMI-BIA | 0.225 | 0.172 | 0.416 | 0.285 | 0.916 | 0.167 |
| PhA-BIA | 0.109 | 0.028 * | 0.027 * | 0.109 | 0.206 | 1.000 |
Abbreviations: IG, Intervention Group; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA, Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale, 6MWT, 6 Minute Walking Test; SPPB, Short Physical Performance Battery; BMI, Body Mass Index; SMI-BIA, Skeletal Muscle Index Bio Impedance Analysis; Pha BIA, Phase Angle Bio Impedance Analysis; * p-value < 0.05. The underline indicates the various outcome measures.
CG at baseline (T0), 2 months after the beginning of exercise (end of treatment) (T1), at 2 (T2) and 4 (T3) months from the end of the exercise training; p-value within CG.
| CG ( | Follow-up | |||||
|---|---|---|---|---|---|---|
| t0vst1 | t0vst2 | t0vst3 | t1vst2 | t1vst3 | t2vst3 | |
|
| ||||||
| QL2 | 0.715 | 1.000 | 0.066 | 0.141 | 0.066 | 0.109 |
| PF2 | 0.102 | 1.000 | 0.180 | 0.655 | 0.109 | 0.109 |
| RF2 | 0.357 | 1.000 | 0.109 | 0.066 | 0.066 | 1.000 |
| EF | 1.000 | 0.066 | 0.715 | 0.109 | 0.144 | 0.715 |
| CF | 0.276 | 0.066 | 0.066 | 0.102 | 0.102 | 1.000 |
| SF | 0.285 | 0.285 | 0.180 | 0.285 | 0.180 | 0.180 |
| FA | 0.180 | 0.144 | 0.144 | 0.068 | 0.068 | 0.715 |
| NV | 0.317 | 0.317 | 0.655 | 1.000 | 0.317 | 0.317 |
| PA | 0.593 | 0.276 | 0.180 | 0.276 | 1.000 | 0.655 |
| DY | 0.317 | 0.317 | 1.000 | 1.000 | 0.317 | 0.317 |
| SL | 0.655 | 0.141 | 0.180 | 0.276 | 0.317 | 0.655 |
| AP | 0.317 | 1.000 | 0.317 | 0.655 | 1.000 | 0.655 |
| CO | 0.317 | 0.655 | 1.000 | 0.655 | 0.564 | 0.655 |
| DI | 0.317 | 0.317 | 0.317 | 0.317 | 0.655 | 0.655 |
| FI | 1.000 | 0.317 | 0.317 | 0.317 | 0.317 | 0.317 |
|
| ||||||
| Global | 1.000 | 0.066 | 0.066 | 0.066 | 0.066 | 0.785 |
|
| ||||||
| Anxiety | 0.581 | 0.141 | 0.197 | 1000 | 0.109 | 0.785 |
| Depression | 0.715 | 0.465 | 0.285 | 0.715 | 0.197 | 0.854 |
|
| ||||||
| SMWT | 0.225 | 0.223 | 0.860 | 0.138 | 0.155 | 0.715 |
| HANDGRIP | 0.465 | 0.465 | 0.465 | 0.465 | 0.083 | 0.705 |
| SPPB | 1.000 | 0.414 | 1.000 | 0.414 | 1.000 | 0.414 |
|
| ||||||
| BMI | 0.144 | 0.078 | 0.078 | 1.000 | 0.713 | 0.063 |
| SMI-BIA | 0.176 | 0.176 | 0.131 | 0.109 | 0.109 | 0.593 |
| PHA-BIA | 0.786 | 0.588 | 0.498 | 0.180 | 0.180 | 1.000 |
Abbreviations: CG, Control Group; EORTC, European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA,6 Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale, 6MWT, 6 Minute Walking Test; SPPB, Short Physical Performance Battery; BMI, Body Mass Index; SMI-BIA, Skeletal Muscle Index Bio Impedance Analysis; Pha BIA, Phase Angle Bio Impedance Analysis; The underline indicates the various outcome measures.